N. Suzuki

发表

Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates

T. Tsukamoto, K. Murakami, M. Shimojo, 2012, Brain Research.

Contribution of Hypothermia and CB1 Receptor Activation to Protective Effects of TAK-937, a Cannabinoid Receptor Agonist, in Rat Transient MCAO Model

T. Tsukamoto, K. Murakami, M. Shimojo, 2012, PloS one.

T257. The Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in N-Methyl-D-Aspartate Receptor Antagonist-Induced Rat Models of Schizophrenia

T. Taniguchi, M. Miyamoto, Hiroki Iwashita, 2018, Biological Psychiatry.

Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma.

G. Kuwajima, W. Abraham, M. Deguchi, 2015, European journal of pharmacology.

Synergistic effect of PGD2 via prostanoid DP receptor on TNF-alpha-induced production of MCP-1 and IL-8 in human monocytic THP-1 cells.

M. Nagira, M. Deguchi, A. Arimura, 2007, European journal of pharmacology.

A prostaglandin D2 receptor antagonist modifies experimental asthma in sheep

K. Yasui, W. Abraham, M. Deguchi, 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models

Hiroki Iwashita, N. Suzuki, M. Nakashima, 2019, Behavioural Brain Research.

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.

H. Kokubo, H. Oki, T. Taniguchi, 2017, Journal of medicinal chemistry.

FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia

Y. Shimizu, K. Nishiyama, H. Komatsu, 2017, The Journal of Pharmacology and Experimental Therapeutics.

The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models

H. Kimura, N. Suzuki, Kazunori Suzuki, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement

S. Sogabe, Y. Kosugi, T. Kaku, 2021, Scientific Reports.

Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia

H. Kimura, N. Suzuki, Motohisa Suzuki, 2019, Pharmacology research & perspectives.

TAK-137, an AMPA-R potentiator with little agonistic effect, has a wide therapeutic window

S. Sogabe, Y. Kosugi, T. Kaku, 2018, Neuropsychopharmacology.

LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models

H. Oki, S. Igaki, Ryuji Yamada, 2021, Science Advances.

Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: Therapeutic time window, combination with t-PA and efficacy in aged rats

T. Tsukamoto, K. Murakami, M. Shimojo, 2013, Brain Research.

Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice

T. Kaisho, S. Takekawa, H. Fujita, 2017, International Journal of Obesity.